Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLC901 in Mild to Moderate Alzheimer's Disease
NCT07191028Phase 3Not yet recruiting
- Sponsor
- Moleac
- Start
- Aug 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mlc901 in Alzheimer's disease (AD), sponsored by Moleac. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mlc901
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07191028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191028.